Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis

Kyla H Thomas, Richard M Martin, Duleeka W Knipe, Julian P T Higgins, David Gunnell

ABSTRACT

OBJECTIVE

To determine the risk of neuropsychiatric adverse events associated with use of varenicline compared with placebo in randomised controlled trials.

DESIGN

Systematic review and meta-analysis comparing study effects using two summary estimates in fixed effects models, risk differences, and Peto odds ratios.

DATA SOURCES

Medline, Embase, PsycINFO, the Cochrane Central Register of Controlled Trials (CENTRAL), and clinicaltrials.gov.

ELIGIBILITY CRITERIA FOR SELECTING STUDIES

Randomised controlled trials with a placebo comparison group that reported on neuropsychiatric adverse events (depression, suicidal ideation, suicide attempt, suicide, insomnia, sleep disorders, abnormal dreams, somnolence, fatigue, anxiety) and death. Studies that did not involve human participants, did not use the maximum recommended dose of varenicline (1 mg twice daily), and were cross over trials were excluded.

RESULTS

In the 39 randomised controlled trials (10 761 participants), there was no evidence of an increased risk of suicide or attempted suicide (odds ratio 1.67, 95% confidence interval 0.33 to 8.57), suicidal ideation (0.58, 0.28 to 1.20), depression (0.96, 0.75 to 1.22), irritability (0.98, 0.81 to 1.17), aggression (0.91, 0.52 to 1.59), or death (1.05, 0.47 to 2.38) in the varenicline users compared with placebo users. Varenicline was associated with an increased risk of sleep disorders (1.63, 1.29 to 2.07), insomnia (1.56, 1.36 to 1.78), abnormal dreams (2.38, 2.05 to 2.77), and fatigue (1.28, 1.06 to 1.55) but a reduced risk of anxiety (0.75, 0.61 to 0.93). Similar findings were observed when risk differences were reported. There was no evidence for a variation in depression and suicidal ideation by age group, sex, ethnicity, smoking status, presence or absence of psychiatric illness, and type of study sponsor (that is, pharmaceutical industry or other).

CONCLUSIONS

This meta-analysis found no evidence of an increased risk of suicide or attempted suicide, suicidal ideation, depression, or death with varenicline. These findings provide some reassurance for users and prescribers regarding the neuropsychiatric safety of varenicline. There was evidence that varenicline was associated with a higher risk of sleep problems such as insomnia and abnormal dreams. These side effects, however, are already well recognised.

SYSTEMATIC REVIEW REGISTRATION

PROSPERO 2014:CRD42014009224.

WHAT IS ALREADY KNOWN ON THIS TOPIC

Varenicline is a commonly prescribed and effective drug for smoking cessation. The Medicines and Healthcare Products Regulatory Agency (MHRA) and Food and Drug Administration (FDA) have issued safety warnings regarding suicidal thoughts and depression associated with the use of varenicline, based on reports from spontaneous reporting systems.

Evidence from previous observational cohort studies and a meta-analysis of 17 trials sponsored by Pfizer have found no evidence of an association with suicide, non-fatal self harm, or depression.

Concerns have been raised about the validity of these findings as observational studies are prone to confounding and industry sponsored trials are more likely than other trials to report outcomes that are favourable to the study sponsor.

WHAT THIS PAPER ADDS

Our meta-analysis of all published randomised controlled trials is the most comprehensive meta-analysis of neuropsychiatric adverse events associated with varenicline use to date, and reports effects using two summary statistics, a relative measure (Peto odds ratio) and an absolute measure (risk difference).

There was no evidence of an increased risk of suicide or attempted suicide, suicidal ideation, depression, or death in varenicline users compared with placebo users.

Varenicline was associated with an increased risk of sleep disorders, insomnia, and abnormal dreams, side effects that are already well recognised and included in patient information leaflets for varenicline.

Introduction

Smoking is the major avoidable cause of preventable morbidity and premature mortality in the United Kingdom and internationally.1,2 Researchers have estimated that smoking related illnesses cost the National Health Service (NHS) about £5bn (£7bn, $8bn) annually.3 Varenicline was first licensed in the UK in 2006. Randomised controlled trials have shown it to be the most clinically effective drug for short term abstinence in smoking cessation.4 Concerns about its neuropsychiatric safety, however, led the Medicines and Healthcare Products Regulatory Agency (MHRA) to issue warnings about varenicline in the UK in 2008.5 Similarly, since 2009, the United States Food and Drug Administration (FDA) has required the addition of a black box warning (the strongest safety warning that can be issued by the agency) to the labelling of varenicline.6 These warnings were based on spontaneous reports of adverse drug reactions from the yellow card scheme and the FDA adverse events reporting system.

Since the original safety warnings, several studies have investigated the neuropsychiatric safety of varenicline.7–10 Most of the studies were observational cohorts,9,10 although one study examined the risk in a meta-analysis of 17 industry sponsored trials.10 None of
the studies found evidence of an increased risk of depression, suicide, or non-fatal self-harm with varenicline. Two major concerns, however, have been raised about the validity of these findings. Firstly, observational studies are prone to confounding by indication. For example, the use of drugs for smoking cessation might seem to be associated with an increased risk of suicide because smokers themselves are at increased risk of mental illness and suicide. Secondly, there is evidence that industry sponsored trials are more likely than other trials to report outcomes that are favourable to the study sponsor. Though the number of prescriptions items of varenicline dispensed in England increased from 499 in 2006 to a peak of almost a million in 2011, there was a 25% decrease from 2011 to 2013. This might reflect ongoing fears among prescribers and patients regarding varenicline’s safety.

We conducted a systematic review and meta-analysis to determine the risk of neuropsychiatric adverse events and death in all published placebo controlled randomised controlled trials of varenicline. This review deals with some of the limitations of the previous studies and is the most comprehensive published review to date of the neuropsychiatric safety of varenicline.

Methods
Eligibility and literature search
We sought all placebo controlled randomised controlled trials of any duration in humans of varenicline at the maximum dose (1 mg twice daily) as described in the recommended standard titration regimen for varenicline (www.chantix.com). We included studies in smokers and non-smokers. We conducted searches of computer databases and online clinical trial registries (Medline, Embase, PsycINFO, the Cochrane Central Register of Controlled Trials (CENTRAL) and clinicaltrials.gov). The search strategy is shown in appendix 1. The searches were performed from the inception of each of the databases to 9 May 2014. There were no language restrictions. We manually searched reference lists of relevant research articles and previous systematic reviews.

Outcome measures
Our primary outcome measures were neuropsychiatric adverse events comprising suicide, attempted suicide, suicidal ideation, and depression. Secondary outcomes included other neuropsychiatric outcomes (abnormal dreams, aggression, anxiety, fatigue, insomnia, irritability, sleep disorders, somnolence) and death. We included all deaths, regardless of whether or not we believed they were related to drug treatment.

Data extraction and management
Two reviewers (KHT and DWK) independently screened the identified studies by title and abstract against the eligibility criteria. We then obtained full reports of studies for a second round of screening. We identified duplicate publications for exclusion by examining the study name, authors, study population, location, and the dates of duration of the study. A third reviewer (DG) reviewed all excluded studies and studies when there was disagreement regarding inclusion or exclusion.

KHT (all papers) and DG and RMM (papers equally shared) performed double data extraction to collect information on the study design (duration of treatment, description of allocation concealment, and blinding), study participants (inclusion and exclusion criteria, country, region, population studied, and baseline characteristics such as ethnicity, sex, smoking history), description of the intervention and placebo groups, primary and secondary outcomes, measures of efficacy of treatment, losses to follow-up, and study sponsor. KHT contacted authors of all studies to verify the accuracy of the extracted data.

Assessment of risk of bias
The Cochrane tool for assessing the risk of bias was used to assess whether there was high, low, or unclear risk of bias in the following domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other sources of bias. KHT (all papers) and DG and RMM (papers equally shared) assessed the risk of bias. Discrepancies were resolved by referring to the original publications and discussion among all three reviewers. KHT also contacted study authors to obtain study protocols and additional information that might not have been published to aid with assessment of the risk of bias.

Statistical analysis
We described study characteristics according to sample size, characteristics of study participants, study duration, duration of treatment, and source of funding. For trials with more than two intervention groups, we extracted data for the maximum dose of varenicline (that is, 1 mg twice daily) and the placebo group. The “metan” command in Stata (version 13, StataCorp, USA) was used to conduct all of the meta-analyses. Because our outcomes of interest are rare, we followed recommendations of Bradburn and colleagues and used Peto odds ratios to compare the varenicline and placebo groups. We also undertook meta-analyses using Mantel-Haenszel risk differences. We report results including 95% confidence intervals and forest plots for both measures so that findings can be compared. Statistical heterogeneity was assessed with the I² statistic.

For sensitivity analyses, we used inverse variance methods under fixed and random effects models for the outcomes with the largest number of treatment events; random effects models can be problematic for meta-analyses of rare events. We report subgroup analyses for the primary outcomes by age (<40 v ≥40), sex (<50% male v ≥50% male), ethnicity (<50% white v ≥50% white), presence or absence of psychiatric illness, smoking status (smokers including smokeless tobacco users v majority non-smokers (>60% non-smokers)), and whether or not the study was sponsored by a pharmaceutical company. Studies were not categorised as sponsored by a pharmaceutical...
company if the drug was provided at no cost by the manufacturer and/or if the research was investigator initiated—that is, the drug and some funding was provided by the manufacturer although there was no other involvement in study conduct or publication and data were independently held by the researchers. Tests for subgroup differences were performed. Funnel plot asymmetry was assessed for two outcome—depression and insomnia—with Harbord’s modified test for small study effects with the “metafunnel” and “metabias” commands in Stata.22 23

Results
Study characteristics
Figure 1 summarises the selection of studies. The search strategy identified 1089 studies from the computerised databases (476 from Medline, 517 from PsyclINFO, and 96 from Embase). One additional trial was identified from CENTRAL and clinical.trials.gov. Out of the 1090 studies, 130 were duplicates and 905 were excluded based on screening of titles and abstracts; therefore 55 papers met the criteria for further screening. After the second round of screening, 42 trials were identified for further data extraction.26–45 Two additional studies were identified when the search was repeated for the week beginning Monday 4 August 2014.46 47 Forty four studies were included in the systematic review. We received responses from study authors for 33 studies (75%).

Table 1 and appendix 2 describe study characteristics. The trials included 1146 participants (6015 patients were randomised to receive a maximum of varenicline 1 mg twice daily and 5131 patients received a placebo). Of these randomised patients, 10998 were evaluable for adverse events (5931 in the varenicline group and 5067 in the placebo group). The duration of treatment ranged from one week to 52 weeks, while study duration ranged from eight days to 53 weeks. Eighteen trials (61.3% of all participants) included cigarette smokers from the general population with no history of psychiatric illnesses (Table 2). In trials that included cigarette smokers (39 trials) participants smoked an average of 20 cigarettes a day for 26.6 years in the varenicline group and 20 cigarettes a day for 26.2 years in the placebo group. Loss to follow-up ranged from 0% to 60% in both groups (appendix 2). In 12 trials losses to follow-up were higher in the varenicline group than the placebo group, whereas in 17 trials losses to follow-up were higher in the placebo group than the varenicline group.

Table 3 shows the assessment of risk of bias. We excluded five trials from the meta-analysis as the risk of bias was unclear in four or more of the six domains47 52 60 or because no data were reported in the published papers and the study authors did not respond to our requests for data.48 49 52 This resulted in exclusion of 114 patients (1.9%) from the varenicline group and 123 patients (2.4%) from the placebo group; 10761 patients were included in the meta-analyses (5817 in the varenicline group and 4944 in the placebo group). In three trials39 41 42 there were high losses to follow-up, 53.7%, 60%, and 45.2%, respectively. These studies were assessed as low risk of bias because of incomplete outcome data and were not excluded. They were all small trials (combined total of n=92 in the varenicline group (1.6% of all people randomised to varenicline in our meta-analysis) and n=86 in the placebo group (1.7% of all people randomised to placebo)). In addition, only nine out of 178 patients (5.1%) were lost to follow-up because of adverse events, and these were mostly gastrointestinal in nature (such as nausea and vomiting).39 42 41

Fig 1 | Flow chart showing selection of randomised controlled trials for inclusion in systematic review of varenicline

Risk of neuropsychiatric adverse events and death
Two people died by suicide (both in the varenicline arm) and four attempted to do so (two in the varenicline arm and two in the placebo arm). Table 4 summarises the Peto odds ratios, risk differences, and 95% confidence interval for the primary and secondary outcomes. Because of the small numbers of events, we combined suicide and attempted suicide into a single outcome. Thirty one trials reported suicide and suicide attempt; the Peto odds ratio for varenicline versus placebo was 1.67 (95% confidence interval 0.33 to 8.57; P=0.05, I²=10.3%) and the risk difference was 0.0003 (−0.002 to 0.003; P=0.81, I²=0.0%). Twenty trials reported suicidal ideation (figs 2 and 3); the Peto odds ratio was 0.58 (0.28 to 1.20; P=0.14, I²=0.0%) and the risk difference was −0.003 (−0.009 to 0.002; P=0.24, I²=0.0%). Thirty one trials reported on depression (figs 4 and 5); the Peto odds ratio was 0.96 (0.75 to 1.22; P=0.74, I²=0.0%) and the risk difference was −0.001 (−0.01 to 0.01; P=0.74, I²=0.0%). Death was reported in 36 trials (total 13/5760 in the varenicline group and 11/4887 in the placebo group). The Peto odds ratio for death was 1.05 (0.47 to 2.38; P=0.9, I²=38.7%), and
there was no evidence of an increased risk of death in the varenicline group compared with the placebo group (risk difference 0.0001, −0.003 to 0.003; \( P = 0.94, I^2 = 0.0\%) (Table 4). The forest plots for the secondary outcomes are shown in appendix 3.

We found no evidence of an increased risk of irritability (odds ratio 0.98, 5\% confidence interval 0.81 to 1.17; \( P = 0.79, I^2 = 0.0\%\)), aggression (0.91, 0.52 to 1.59; \( P = 0.75, I^2 = 20.8\%\)), or somnolence (1.23, 0.94 to 1.62; \( P = 0.13, I^2 = 10.4\%\)) as the confidence intervals included the null value of 1. Varenicline was associated with an increased risk of sleep disorders (1.63, 1.29 to 2.07; \( P < 0.001, I^2 = 0.0\%\)), insomnia (1.56, 1.36 to 1.78; \( P < 0.001, I^2 = 0.0\%\)), abnormal dreams (2.38, 2.05 to 2.77; \( P < 0.001, I^2 = 22.3\%\)), and fatigue (1.28, 1.06 to 1.55; \( P = 0.01, I^2 = 6.3\%\)), with some evidence of a reduced risk of anxiety (0.75, 0.61 to 0.93; \( P = 0.008, I^2 = 5.7\%\)). Consistent findings were observed for the risk differences (table 4).

Sensitivity analyses
There were minimal differences in the effect measures and 95\% confidence intervals with Peto, fixed effects, and random effects odds ratios (Table 5).

Subgroup analyses
The subgroup analyses are shown in appendix 4 for the primary outcomes of depression and suicidal ideation. Subgroup tests showed no evidence of a variation in the
side effects of depression and suicidal ideation by age group ($P=0.391$ and $P=0.933$, respectively, for interaction), percentage of men in the study ($P=0.418$ and $P=0.925$), percentage of white people in the study ($P=0.685$ and $P=0.254$), presence or absence of psychiatric illness ($P=0.126$ and $P=0.304$), smoking status ($P=0.906$ for depression but not calculated for suicidal ideation as there were no reports of suicidal ideation in studies that included non-smokers), and whether the trial was industry sponsored or not ($P=0.386$ and $P=0.380$). The effect estimates (odds ratio) for the trials in which all participants had psychiatric illnesses compared with those where none of the participants had psychiatric illness were $1.49$ (95% confidence interval $0.84$ to $2.65$) versus $0.91$ (0.69 to 1.21) for depression and $0.79$ (0.32 to 1.93) versus $0.34$ (0.09 to 1.29) for suicidal ideation.

Table 2 | Summary of characteristics of patients enrolled in 44 randomised controlled trials of varenicline

<table>
<thead>
<tr>
<th>Characteristics of trial participants</th>
<th>No of trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smokers from general population</td>
<td>18</td>
</tr>
<tr>
<td>Smokers with psychiatric illness</td>
<td>8</td>
</tr>
<tr>
<td>Heavy drinking smokers/alcohol dependence</td>
<td>4</td>
</tr>
<tr>
<td>People dependent on cocaine or opioid dependence</td>
<td>3</td>
</tr>
<tr>
<td>Smokeless tobacco users</td>
<td>2</td>
</tr>
<tr>
<td>Smokers with mild to moderate COPD</td>
<td>1</td>
</tr>
<tr>
<td>Smokers with cardiovascular disease</td>
<td>1</td>
</tr>
<tr>
<td>Smokers about to undergo surgery</td>
<td>1</td>
</tr>
<tr>
<td>Patients with spinocerebellar ataxia type 3</td>
<td>1</td>
</tr>
<tr>
<td>Elderly non-smokers</td>
<td>1</td>
</tr>
<tr>
<td>Smokers in hospital</td>
<td>1</td>
</tr>
<tr>
<td>Smokers previously treated with varenicline</td>
<td>1</td>
</tr>
<tr>
<td>Ex-smokers on long term NRT</td>
<td>1</td>
</tr>
</tbody>
</table>

Table 3 | Risk of bias assessment for each trial of varenicline using Cochrane risk of assessment of bias tool

<table>
<thead>
<tr>
<th>Study</th>
<th>Random sequence generation</th>
<th>Allocation concealment used</th>
<th>Blinding Participants and personnel</th>
<th>Outcome assessment</th>
<th>Incomplete outcome data</th>
<th>Selective reporting</th>
<th>Other bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthenelli 2013$^{34}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Bolliger 2017$^{35}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Brandon 2011$^{36}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Burstein 2006$^{37}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Chengappa 2014$^{38}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Cinciripini 2013$^{39}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Ebbert 2011$^{40}$</td>
<td>Low</td>
<td>Unclear</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Evins 2014$^{41}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Faessel 2009$^{42}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Fagerstrom 2010$^{43}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Fatemi 2013$^{44}$</td>
<td>Unclear</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Garza 2013$^{45}$</td>
<td>Unclear</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Gonzales 2066$^{46}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Gonzales 2014$^{47}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Hughes 2011$^{48}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Jorenby 2010$^{49}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Litten 2013$^{50}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>McClure 2013$^{51}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>McKe 2009$^{52}$</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Low</td>
<td>Unclear</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Meszaros 2013$^{53}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Mitchell 2012$^{54}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Nakamura 2007$^{55}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Niaura 2008$^{56}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Nides 2006$^{57}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Oncken 2006$^{58}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Plebani 2012$^{59}$</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Plebani 2013$^{60}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Unclear</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Poling 2010$^{61}$</td>
<td>Low</td>
<td>Unclear</td>
<td>Low</td>
<td>Unclear</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Rennard 2012$^{62}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Rigotti 2010$^{63}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Shim 2013$^{64}$</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Stein 2013$^{65}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Steinberg 2011$^{66}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Tashkin 2011$^{67}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Tonnesen 2013$^{68}$</td>
<td>Low</td>
<td>Unclear</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Tonstad 2006$^{69}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Tsai 2007$^{70}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Wang 2009$^{71}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Weiner 2011$^{72}$</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Williams 2007$^{73}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Williams 2012$^{74}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Wong 2012$^{75}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Zesiewicz 2012$^{76}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Zhao 2011$^{77}$</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Unclear</td>
<td>Low</td>
</tr>
</tbody>
</table>
varenicline use in 20 placebo controlled randomised trials

**Table 4 | Summary of Peto odds ratios, risk differences, and 95% confidence intervals for neuropsychiatric events in people treated with varenicline**

<table>
<thead>
<tr>
<th>Neuropsychiatric adverse event</th>
<th>No of events/No treated</th>
<th>Varenicline group</th>
<th>Placebo group</th>
<th>Odds ratio (95% CI), P value</th>
<th>Risk difference (95% CI), P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary outcomes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression</td>
<td>163/5356</td>
<td>139/4487</td>
<td>0.96 (0.75 to 1.22), 0.74</td>
<td>–0.001 (–0.01 to 0.00), 0.74</td>
<td></td>
</tr>
<tr>
<td>Suicidal ideation</td>
<td>15/2799</td>
<td>18/2191</td>
<td>0.58 (0.28 to 1.20), 0.14</td>
<td>–0.003 (–0.009 to 0.002), 0.24</td>
<td></td>
</tr>
<tr>
<td>Attempted suicide</td>
<td>2/2184</td>
<td>2/1842</td>
<td>0.75 (0.10 to 5.65), 0.78</td>
<td>–0.0003 (–0.005 to 0.004), 0.91</td>
<td></td>
</tr>
<tr>
<td>Suicide and attempted suicide</td>
<td>4/5352</td>
<td>2/4478</td>
<td>1.67 (0.33 to 8.57), 0.54</td>
<td>0.0003 (–0.002 to 0.003), 0.81</td>
<td></td>
</tr>
<tr>
<td><strong>Secondary outcomes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abnormal dreams</td>
<td>603/5606</td>
<td>224/4741</td>
<td>2.38 (2.05 to 2.77), &lt;0.001</td>
<td>0.06 (0.05 to 0.07), &lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Aggression</td>
<td>39/4276</td>
<td>24/3524</td>
<td>0.91 (0.52 to 1.59), 0.75</td>
<td>–0.001 (–0.005 to 0.004), 0.79</td>
<td></td>
</tr>
<tr>
<td>Anxiety</td>
<td>209/4999</td>
<td>226/4457</td>
<td>0.75 (0.61 to 0.93), 0.008</td>
<td>–0.01 (–0.02 to –0.003), 0.01</td>
<td></td>
</tr>
<tr>
<td>Death</td>
<td>13/5760</td>
<td>11/4887</td>
<td>1.05 (0.47 to 2.38), 0.9</td>
<td>0.0001 (–0.003 to 0.003), 0.94</td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>283/5502</td>
<td>202/4701</td>
<td>1.28 (1.06 to 1.55), 0.01</td>
<td>0.01 (0.002 to 0.02), 0.01</td>
<td></td>
</tr>
<tr>
<td>Insomnia</td>
<td>679/5621</td>
<td>379/4762</td>
<td>1.56 (1.36 to 1.78), &lt;0.001</td>
<td>0.04 (0.03 to 0.05), &lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Irritability</td>
<td>293/5406</td>
<td>266/4615</td>
<td>0.98 (0.81 to 1.17), 0.79</td>
<td>–0.001 (–0.01 to 0.008), 0.79</td>
<td></td>
</tr>
<tr>
<td>Sleep disorders</td>
<td>211/5081</td>
<td>123/4284</td>
<td>1.63 (1.29 to 2.07), &lt;0.001</td>
<td>0.02 (0.01 to 0.02), &lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Somnolence</td>
<td>139/5360</td>
<td>91/4542</td>
<td>1.23 (0.94 to 1.62), 0.13</td>
<td>0.005 (–0.001 to 0.001), 0.13</td>
<td></td>
</tr>
</tbody>
</table>

**Study** | **No of events/total treatment control** | **Odds ratio (95% CI)** | **Weight (%)** | **Odds ratio (95% CI)**
Jorenby 2006 | 0/343 1/340 | 0.13 (0.00 to 0.0676) | 3 | 0.13 (0.00 to 0.0676)
Hughes 2011 | 0/107 1/111 | 0.14 (0.00 to 0.708) | 3 | 0.14 (0.00 to 0.708)
Bolliger 2011 | 2/390 0/198 | 6.53 (0.24 to 85.23) | 23 | 0.84 (0.19 to 3.80)
Tashkin 2011 | 0/248 1/251 | 0.14 (0.00 to 0.69) | 8 | 0.11 (0.01 to 1.51)
Williams 2012 | 5/84 3/43 | 0.13 (0.00 to 0.641) | 3 | 0.13 (0.00 to 0.641)
Rennard 2012 | 1/486 2/165 | 3.66 (0.03 to 387.84) | 2 | 0.16 (0.00 to 8.42)
Mitchell 2012 | 0/33 1/31 | 1.00 (0.09 to 11.03) | 9 | 1.00 (0.09 to 11.03)
Stein 2013 | 1/111 0/33 | 1.14 (0.01 to 1.36) | 10 | 1.14 (0.01 to 1.36)
Cinciripini 2013 | 0/86 1/106 | 1.18 (0.16 to 8.75) | 13 | 1.18 (0.16 to 8.75)
Meszaros 2013 | 2/5 2/5 | 1.86 (0.19 to 18.64) | 10 | 1.86 (0.19 to 18.64)
Anthenelli 2013 | 0/256 3/269 | Excluded | 0 | Excluded
Evins 2014 | 0/40 2/47 | Excluded | 0 | Excluded
Chengappa 2014 | 2/31 1/29 | Excluded | 0 | Excluded
Zhao 2011 | 0/14 1/10 | Excluded | 0 | Excluded
Brandon 2011 | 0/46 0/54 | Excluded | 0 | Excluded
Ebbert 2011 | 0/38 0/38 | Excluded | 0 | Excluded
Steinberg 2011 | 0/40 0/39 | Excluded | 0 | Excluded
Wong 2012 | 0/151 0/135 | Excluded | 0 | Excluded
McClure 2013 | 0/41 0/42 | Excluded | 0 | Excluded
Gonzales 2014 | 0/249 0/245 | Excluded | 0 | Excluded

**Overall:** I^2 = 0%, P=0.621

Fig 2 | Forest plot of risk of suicidal ideation events (Peto odds ratio) associated with varenicline use in 20 placebo controlled randomised trials

**Comparison with other studies**

A recent study by Kishi and Iwata examined the effects of varenicline for smoking cessation in people with schizophrenia in a meta-analysis of seven randomised controlled trials.\(^6^8\) With the exception of the study by Hong and colleagues,\(^6^9\) we included all their randomised controlled trials in the current analysis. Similar to our findings, Kishi and Iwata found no significant differences in depression and suicidal ideation between the varenicline and placebo groups. They reported, however, that varenicline use was associated with a lower risk of abnormal dreams/nightmares than placebo (relative risk 0.47, 95% confidence interval 0.22 to 0.99; P=0.05).\(^6^8\)

**Small study effects**

The funnel plots for depression and insomnia are shown in appendix 5. The P values for funnel plot asymmetry were 0.53 for depression and 0.93 for insomnia (that is, there was no evidence against the null hypothesis of no small study effects).

**Discussion**

This meta-analysis of 39 randomised controlled trials, involving 5817 patients prescribed varenicline 1 mg twice daily and 4944 patients prescribed placebo, found no increased risk of suicide or attempted suicide, suicidal ideation, depression, or death in individuals treated with varenicline. Almost half of the trial participants were chronic heavy smokers (that is, they had smoked on average 20 cigarettes a day for 26 years). Five separate trials (including 1281 participants randomised to varenicline and 1143 to placebo) reported a suicide and/or suicide attempt (see appendix 3); one reported suicide only, three reported attempted suicide only, and one reported both suicide and attempted suicide. Two suicides and two attempts occurred in the varenicline group of the trials (0.08%) and two attempts occurred in the placebo group (0.05%). Use of the maximum dose of varenicline (1 mg twice daily) was associated with a 28% increased risk of fatigue, a 56% increased risk of insomnia, a 63% increased risk of sleep disorders, and more than twice the risk of abnormal dreams. There was evidence of a 25% reduction in the risk of anxiety. When we used risk differences, for every 1000 patients there were an additional 10 cases of fatigue, 60 cases of insomnia, 20 cases of sleep disorders, and 60 cases of abnormal dreams in those prescribed varenicline compared with placebo. Similarly, there were 10 fewer episodes of anxiety per 1000 participants in the varenicline group compared with the placebo group (risk difference –0.01, 95% confidence interval –0.02 to –0.003). There was no evidence of a variation in depression and suicidal ideation by age, sex, ethnicity, presence or absence of psychiatric illness, or type of study sponsor.
Overall, the study found increased risk of irritability (1.14, 0.75 to 1.73), which is consistent with our findings. A previous Cochrane review examined the efficacy and tolerability of nicotine receptor partial agonists including varenicline. Trials were excluded if participants used smokeless tobacco or if there was less than six months of follow-up. In addition to the efficacy outcomes, meta-analyses were performed for the most commonly reported adverse events: nausea, insomnia, abnormal dreams, and headache. Findings were consistent with our study for insomnia (relative risk 1.62, 95% confidence interval 1.40 to 1.88) and abnormal dreams (2.91, 2.34 to 3.62).

### Strengths and limitations

To the best of our knowledge, this is the most comprehensive published systematic review (and meta-analysis) of neuropsychiatric effects associated with use of varenicline. Compared with the previous Cochrane review, our analysis included 16 additional trials for the meta-analysis of the risk of insomnia events and 23 additional trials for the pooled analysis of abnormal dreams.

The choice of summary statistics for meta-analyses of rare events caused controversy (about whether the Peto odds ratio should be reported instead of risk differences) when it led to conflicting findings from two systematic reviews examining the risk of cardiovascular side effects associated with varenicline use. We present results using both measures: a relative measure (Peto odds ratio and sensitivity analyses with fixed and random effects odds ratios) as well as an absolute measure (risk difference). Findings were consistent for all examined outcomes.

Many study authors did not specify the actual dates that adverse events were reported so we included all reported events; this decision would have increased the likelihood of obtaining reports of rare adverse events. We contacted authors for all of our included trials to check the data extracted on adverse events and for study protocols and other information to adequately assess the risk of bias in the studies. We had a high response rate (75%).

There are some limitations. Firstly, in this analysis we used study level data instead of individual level data so we were unable to determine whether differences in the adverse events were because of greater quit rates in the varenicline group relative to placebo. Secondly, because of the small number of suicides and attempted suicide reported (n=6), we cannot rule out major beneficial or adverse effects of varenicline for this outcome (Peto odds ratio 1.67, 95% confidence interval 0.33 to 8.57). Thirdly, there was potential for heterogeneity in the reporting of adverse events. Authors used a range of methods to record adverse events including self report, open ended questions, structured questionnaires, side effect checklists, and case reports coded to the Medical Dictionary for
### Study | No of events/total | Odds ratio (95% CI) | Weight (%) | Odds ratio (95% CI)
--- | --- | --- | --- | ---
Nides 2006 | 2/125 | 1/123 | 1 | 1.93 (0.20 to 18.70)
Tonstad 2006 | 15/602 | 17/604 | 12 | 0.88 (0.44 to 1.78)
Jorenby 2006 | 6/343 | 1/340 | 3 | 4.19 (0.95 to 18.55)
Onken 2006 | 6/253 | 4/121 | 3 | 0.70 (0.18 to 2.67)
Gonzales 2006 | 4/349 | 7/344 | 4 | 0.57 (0.17 to 1.86)
Williams 2007 | 12/251 | 4/126 | 5 | 1.48 (0.51 to 4.28)
Tsai 2007 | 1/126 | 2/124 | 1 | 0.50 (0.05 to 4.88)
Niaura 2008 | 3/157 | 2/155 | 2 | 1.48 (0.25 to 8.64)
Rigotti 2010 | 5/353 | 3/350 | 1 | 1.64 (0.41 to 6.61)
Fagerstrom 2010 | 2/213 | 5/218 | 3 | 0.43 (0.10 to 1.91)
Hughes 2011 | 1/107 | 2/111 | 1 | 0.53 (0.05 to 5.14)
Garza 2011 | 1/55 | 1/55 | 1 | 1.00 (0.06 to 16.19)
Ebbert 2011 | 0/38 | 1/38 | 1 | 0.14 (0.00 to 6.82)
Steinberg 2011 | 2/40 | 2/39 | 1 | 0.97 (0.13 to 7.19)
Bolliger 2011 | 8/390 | 4/198 | 4 | 1.02 (0.30 to 3.40)
Tashkin 2011 | 6/248 | 5/251 | 4 | 1.22 (0.37 to 4.02)
Williams 2012 | 4/84 | 3/43 | 2 | 0.66 (0.13 to 3.26)
Rennard 2012 | 4/486 | 5/165 | 3 | 0.20 (0.04 to 0.90)
Wong 2012 | 2/151 | 2/135 | 2 | 0.89 (0.16 to 4.42)
Zesiewicz 2012 | 0/9 | 2/9 | 1 | 0.12 (0.12 to 2.08)
McClure 2013 | 17/41 | 20/42 | 8 | 0.78 (0.78 to 1.85)
Stein 2013 | 17/111 | 7/33 | 6 | 0.66 (0.66 to 1.85)
Litten 2013 | 7/97 | 6/101 | 5 | 1.23 (1.23 to 3.78)
Cinciripini 2013 | 6/86 | 14/106 | 7 | 0.51 (0.20 to 1.30)
Meszaros 2013 | 1/5 | 1/5 | 1 | 1.00 (0.05 to 19.91)
Anthenelli 2013 | 17/256 | 13/269 | 11 | 1.40 (0.67 to 2.92)
Evins 2014 | 1/40 | 1/47 | 1 | 1.18 (0.07 to 19.32)
Chengappa 2014 | 8/31 | 2/29 | 3 | 3.81 (0.99 to 14.67)
Gonzales 2014 | 5/249 | 2/245 | 3 | 2.34 (0.53 to 10.40)
Faessle 2009 | 0/14 | 0/7 | 0 | Excluded
Brandon 2011 | 0/46 | 0/54 | 0 | Excluded
Overall: I²=0%, P=0.631 163/5356 139/4487

![Fig 4](https://www.europeancommission.europa.eu/delegations/london/files/2023-08-15/Fig4.png)

**Fig 4** | Forest plot of risk of depression events (Peto odds ratio) associated with varenicline use in 31 placebo controlled randomised trials

Regulatory Activities (MedDRA, www.meddra.org). All of the industry sponsored trials coded adverse events using MedDRA. Fourthly, we excluded two studies from the review as the maximum dose of varenicline used in these studies was only 1 mg once a day—that is, half of the recommended maximum dose. Hong and colleagues examined varenicline treatment in 20 smokers and 15 non-smokers with schizophrenia or schizoaffective disorder and found no evidence that varenicline worsened psychiatric symptoms in these patients.69 Mocking and colleagues studied the effects of varenicline on emotional and cognitive processing in 21 healthy adult non-smokers and concluded that it did not cause problems in emotional processing or impulsivity, providing less support for a possible depressive effect of varenicline.73 Furthermore, a secondary analysis, which included all doses of varenicline in the original trials and two excluded randomised controlled trials, produced similar findings to our main analysis (see appendix 6).

We tried to minimise reporting bias by including all events (such as deaths) reported regardless of whether or not we considered them to be related to treatment. It is still possible, however, that reporting bias could have occurred as for certain trials, where the corresponding authors did not respond to our requests for additional information, we could not determine whether a lack of reporting of deaths in the published paper was synonymous with no deaths. It was difficult to interpret the funnel plots to assess whether publication bias might be present as most trials were efficacy trials and were not performed solely to detect the incidence of psychiatric adverse events.

Additionally, smoking cessation has been shown to have a positive impact on mental health outcomes with a reduction in depression and anxiety compared with those who continue to smoke.74 Patients prescribed varenicline were reported to have an approximately threefold increased chance of quitting smoking compared with those given placebo (odds ratio 2.88, 95% confidence interval 2.40 to 3.47); this could explain the reduction in anxiety observed in this meta-analysis.

Lastly, half of the trials were sponsored by Pfizer, the manufacturers of varenicline. Although previous research with nicotine replacement therapy has shown that industry sponsored trials were more likely than other trials to report outcomes that were favourable to the study sponsor,64 we did not find any evidence for differences in depression and suicidal ideation for industry versus non industry sponsored trials (P=0.386 and P=0.380, respectively, for interaction). In addition, all of the industry sponsored trials were assessed overall as having a low risk of bias.

**Conclusions and clinical implications**

Based on this comprehensive systematic review of published randomised controlled trials, there is no evidence of an increased risk of depression, suicidal behaviour (that is, suicide or attempted suicide, suicidal ideation), and death from any cause associated with treatment with varenicline. Varenicline users, however, have an increased risk of abnormal dreams, insomnia, and sleep disturbances, which are consistent with findings from other studies and previously documented commonly reported side effects of varenicline (www.chantix.com). We reported our findings using two summary statistics (a relative measure and an absolute measure) and observed consistency with both methods. This meta-analysis adds to previous research (observational and experimental) that found no evidence for increased suicidal behaviour or depression with varenicline, the most effective drug for smoking cessation.8 The dangers of smoking are well documented, and the health benefits of stopping smoking are well known. Our analysis suggests that the benefits of varenicline for smoking cessation outweigh the as yet unproved risks of suicidal behaviour. In the UK, varenicline is recommended alongside bupropion and nicotine replacement therapy as first line treatment for smoking cessation.75 Therefore, the reduction in varenicline prescribing in the UK should be as much a cause for concern to clinicians, regulatory agencies, and policy makers as the unfounded fears regarding varenicline’s association with suicidal behaviour.
We are grateful to the corresponding authors of the trials and Cristina Ruus of Pfizer (for the Pfizer sponsored trials) for their support with providing access to the data on psychiatric adverse events and death used in this study.

Contributors: KHT, DG and RMM conceived the study. KHT conducted the literature search. KHT and DWK screened the abstracts with assistance from DG. KHT, DG and RMM were responsible for data extraction and the risk of bias assessment. KHT did the statistical analysis with support from JPH. KHT wrote the paper with contributions from all authors. All authors have approved the final draft of the manuscript. KHT is study guarantor, had full access to all of the data (excluding statistical reports and tables) and can take responsibility for the integrity of the data and the accuracy of the data analysis.

Funding: KHT is currently funded by a clinical lectureship from the National Institute for Health Research. Part of this work was undertaken while KHT was on a National Institute for Health Research doctoral research fellowship (DRF-2010-03-138). DWK is funded by a Wellcome Trust four year studentship (WT099874MA). DG is an NIHR senior investigator. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research, or the Department of Health.

Competing interests: All authors have completed the Unified Competing Interest Form at www.icmje.org/coiDisclosure.pdf (available on request from the corresponding author) and declare: RMM had specified relationship with the MHRA in the past (was a member of the MHRA’s Independent Scientific Advisory Committee for CPRD research and received expenses and a small fee for meeting attendance and preparation for meetings). DG had specified relationship with the MHRA in the past (was a member of the MHRA’s Pharmacovigilance Expert Advisory Group and received travel expenses and a small fee for meeting attendance and preparation for meetings).

Ethics approval: Not required.

Data sharing: No additional data are available.

Transparency declaration: KHT affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as published (and, if relevant, registered) have been explained.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.


75 Smoking cessation services in primary care, pharmacies, local authorities and workplaces, particularly for manual working groups, pregnant women and hard to reach communities. NICE public health guidance 10. National Institute for Health and Care Excellence, 2008.

© BMJ Publishing Group Ltd 2015

**Appendix 1:** Search strategy to identify relevant articles in Medline

**Appendix 2:** Further characteristics of included randomised controlled trials

**Appendix 3:** Forest plots for secondary outcomes

**Appendix 4:** Subgroup analyses

**Appendix 5:** Funnel plots

**Appendix 6:** Summary of Peto odds ratios, risk differences, and 95% confidence intervals for neuropsychiatric events